The company currently holds 541
K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest Astri Therapeutics is not taking enough advantage from borrowing.
We provide trade advice to complement the prevailing
expert consensus on Astri Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of Astria Therapeutics using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Astria Therapeutics based exclusively on its
fundamental and basic
technical indicators. By analyzing Astria Therapeutics's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Astria Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Astria Therapeutics. We calculate exposure to Astria Therapeutics's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Astria Therapeutics's related companies.
Astria Therapeutics Investment Alerts
Astria investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Astria Therapeutics performance across your portfolios.Please check all
investment alerts for Astria
Astria Therapeutics Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Astria value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Astria Therapeutics competition to find
correlations between indicators driving the intrinsic value of Astria.
Astria Therapeutics Gross Profit
Astria Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Astria Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Astria Therapeutics Gross Profit growth over the last 10 years. Please check Astria Therapeutics'
gross profit and other
fundamental indicators for more details.
Details
Net Loss for the year was (218.84
M).
Margins Breakdown
Astri profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Astri Therapeutics itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Astri Therapeutics profit margins.
| EBITDA Margin | (51.66) |
| Gross Margin | 0.89 |
| Profit Margin | (53.15) |
Astri Therapeutics Earnings Before Interest Taxes and Depreciation Amortization EBITDA is relatively stable at the moment. Astri Therapeutics Earnings before Tax is decreasing over the last 8 years. Additionally, Astri Therapeutics Average Assets is relatively stable at the moment. Astri Therapeutics Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. The latest value of Astri Therapeutics Earnings Before Interest Taxes and Depreciation Amortization EBITDA is -36,220,263. Astri Therapeutics Earnings before Tax is decreasing over the last 8 years. Additionally, Astri Therapeutics Average Assets is relatively stable at the moment.
Are Astri Therapeutics technical ratios showing a bounce-back?
The value at risk is down to -9.05 as of today. Astri Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize Astri Therapeutics independently to ensure intended market timing strategies are aligned with expectations about Astri Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Astri Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Astri Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Astri Therapeutics Implied Volatility
Astri Therapeutics' implied volatility exposes the market's sentiment of Astri Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Astri Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Astri Therapeutics stock will not fluctuate a lot when Astri Therapeutics' options are near their expiration.
Our Conclusion on Astri Therapeutics
While other companies under the biotechnology industry are still a bit expensive, Astri Therapeutics may offer a potential longer-term growth to retail investors. To conclude, as of the 5th of February 2022, our analysis shows that Astri Therapeutics barely shadows the market. The enterprise is
undervalued and projects
low probability of distress for the next 2 years. Our latest 90 days buy-hold-sell advice on the enterprise is
Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Astria Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
